The correct way to purchase Capmatinib (Tabrecta)

Introduction: In August 2022, the U.S. Food and Drug Administration (FDA) approved capmatinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have mutations that cause mesenchymal epithelial transition (MET) exon 14 skipping. Capmatinib inhibits the proto-oncogene c-MET by selectively binding to the proto-oncogene c-MET, inhibiting phosphorylation and disrupting signal transduction pathways, which can lead to apoptosis in cells overexpressing c-MET.

The correct way to purchase generic drugs of Tabrecta

The correct way to purchase generic drugs of should follow the principles of legality and safety. You can refer to the following .

1. Hospital pharmacies: Capmatinib generics are usually available in hospital pharmacies in countries where they are on the market, such as Laos, Bangladesh, etc. After visiting the hospital, you can purchase the drug directly in the pharmacy with a doctor's prescription.

2. Drug retail stores: Patients can go to local drug retail stores in the countries where it is listed to purchase generic capmatinib.

3. Online pharmacies: Some online pharmacies may provide generic drug sales services of capmatinib, and patients can purchase and order them through the Internet platform.

4. Medical service institutions: Domestic medical service institutions can help purchase the required version of generic drugs, and the versions of generic drugs are relatively complete. Patients can consult them for further information on drug purchase.

Capmatinib (Tabrecta) needs to be taken under the guidance of a doctor. During the medication, pay attention to the adverse drug reactions and precautions.

Adverse reactions of Tabrecta

More than 20% of patients in Tabrecta clinical trials reported symptoms such as edema, nausea, vomiting, musculoskeletal pain, fatigue, dyspnea, cough and loss of appetite. Serious adverse reactions include interstitial lung disease/pneumonitis, hepatotoxicity, pancreatic toxicity, hypersensitivity reactions, photosensitivity, etc.

Precautions for Tabrecta

Verify pregnancy status before starting treatment with Tabrecta, and monitor for new or worsening pulmonary symptoms, such as dyspnea and cough, during treatment. Monitor liver function tests before initiating treatment, every two weeks for the first three months of treatment and monthly or as clinically indicated thereafter, and monitor baseline amylase and lipase levels periodically during treatment.

Capmatinib can increase the blood concentration and effects of caffeine, and patients may need to limit caffeine intake. In addition, capmatinib may cause photosensitivity reactions. Patients should limit direct exposure to the sun during treatment and take appropriate sun protection measures, such as wearing long-sleeved clothing, wearing a hat, and using sunscreen with a high SPF value.